Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

ClinicalTrials.gov ID: NCT02964247

Public ClinicalTrials.gov record NCT02964247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Study identification

NCT ID
NCT02964247
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
303 participants

Conditions and interventions

Interventions

  • liraglutide Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2017
Primary completion
May 3, 2018
Completion
May 7, 2018
Last update posted
Nov 16, 2020

2017 – 2018

United States locations

U.S. sites
56
U.S. states
21
U.S. cities
50
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35294
Novo Nordisk Investigational Site Montgomery Alabama 36109
Novo Nordisk Investigational Site Tucson Arizona 85741
Novo Nordisk Investigational Site Lancaster California 93534
Novo Nordisk Investigational Site Northridge California 91325
Novo Nordisk Investigational Site Sacramento California 95821
Novo Nordisk Investigational Site San Diego California 92111
Novo Nordisk Investigational Site San Ramon California 94583
Novo Nordisk Investigational Site Vista California 92083
Novo Nordisk Investigational Site Gainesville Florida 32653
Novo Nordisk Investigational Site Hollywood Florida 33024
Novo Nordisk Investigational Site Jacksonville Florida 32216
Novo Nordisk Investigational Site Jacksonville Florida 32256
Novo Nordisk Investigational Site Jacksonville Florida 32258
Novo Nordisk Investigational Site Maitland Florida 32751
Novo Nordisk Investigational Site Miami Florida 33165
Novo Nordisk Investigational Site Miami Florida 33176
Novo Nordisk Investigational Site Miami Lakes Florida 33016
Novo Nordisk Investigational Site Tampa Florida 33606
Novo Nordisk Investigational Site Lawrenceville Georgia 30046
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Statesboro Georgia 30461
Novo Nordisk Investigational Site Blackfoot Idaho 83221
Novo Nordisk Investigational Site Evansville Indiana 47714
Novo Nordisk Investigational Site Topeka Kansas 66606
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site New Orleans Louisiana 70115
Novo Nordisk Investigational Site Kalamazoo Michigan 49009
Novo Nordisk Investigational Site Rochester Michigan 48307
Novo Nordisk Investigational Site Billings Montana 59101
Novo Nordisk Investigational Site Henderson Nevada 89052-2649
Novo Nordisk Investigational Site Albany New York 12203
Novo Nordisk Investigational Site West Seneca New York 14224
Novo Nordisk Investigational Site Charlotte North Carolina 28210
Novo Nordisk Investigational Site Charlotte North Carolina 28226
Novo Nordisk Investigational Site Charlotte North Carolina 28277
Novo Nordisk Investigational Site Kinston North Carolina 28501
Novo Nordisk Investigational Site Wilmington North Carolina 28401
Novo Nordisk Investigational Site Cincinnati Ohio 45245
Novo Nordisk Investigational Site Columbus Ohio 43212
Novo Nordisk Investigational Site McMurray Pennsylvania 15317
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15243
Novo Nordisk Investigational Site Moncks Corner South Carolina 29461
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464
Novo Nordisk Investigational Site Myrtle Beach South Carolina 29572
Novo Nordisk Investigational Site Spartanburg South Carolina 29303
Novo Nordisk Investigational Site Memphis Tennessee 38119
Novo Nordisk Investigational Site Nashville Tennessee 37203
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Edinburg Texas 78539
Novo Nordisk Investigational Site Houston Texas 77024
Novo Nordisk Investigational Site Houston Texas 77030
Novo Nordisk Investigational Site Humble Texas 77338
Novo Nordisk Investigational Site Round Rock Texas 78681
Novo Nordisk Investigational Site Schertz Texas 78154
Novo Nordisk Investigational Site Spokane Washington 99201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02964247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2020 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02964247 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →